Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Quince Therapeutics, Inc.
QNCXCurrent price
1.59 USD
-0.13 USD (-7.56%)
Last closed
1.68 USD
Company
www.cortexyme.com
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
73 570 224 USD
Yield for 12 month
+77.18 %
1Y
3Y
5Y
10Y
15Y
QNCX
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
+36 000 USD
Current Year
-322 000 USD
Last Year
-175 000 USD
Current Quarter
-44 000 USD
Last Quarter
-40 000 USD
Key Figures QNCX
1 year
3 years
5 years
10 years
EBITDA
-29 129 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-16.5 %
PEG Ratio
–
Return On Equity TTM
-79.38 %
Wall Street Target Price
12 USD
Revenue TTM
–
Book Value
1.09 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.26 USD
Diluted Eps TTM
-1.26 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics QNCX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History QNCX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation QNCX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
1.4385
Price Book MRQ
1.5664
Financials QNCX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators QNCX
For 52 weeks
0.51 USD
1.79 USD
50 Day MA
0.91 USD
Shares Short Prior Month
1 920 484
200 Day MA
0.93 USD
Short Ratio
30.08
Shares Short
1 911 224
Short Percent
4.78 %
BeatStart